Marshall Wace LLP Reduces Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)

Marshall Wace LLP cut its stake in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 26.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 597,794 shares of the company's stock after selling 212,065 shares during the period. Marshall Wace LLP owned about 1.92% of Acrivon Therapeutics worth $3,599,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Barclays PLC lifted its position in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company's stock valued at $233,000 after buying an additional 11,273 shares in the last quarter. State Street Corp raised its stake in Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company's stock worth $1,581,000 after acquiring an additional 47,233 shares during the period. JPMorgan Chase & Co. lifted its holdings in Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company's stock valued at $238,000 after purchasing an additional 28,748 shares in the last quarter. Exome Asset Management LLC bought a new position in shares of Acrivon Therapeutics in the third quarter worth approximately $817,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Acrivon Therapeutics in the fourth quarter worth $40,000. Institutional investors own 71.62% of the company's stock.

Acrivon Therapeutics Stock Down 3.8 %

NASDAQ ACRV traded down $0.05 on Thursday, reaching $1.35. The company had a trading volume of 311,622 shares, compared to its average volume of 183,667. The stock has a market capitalization of $42.24 million, a PE ratio of -0.50 and a beta of 1.77. Acrivon Therapeutics, Inc. has a 12 month low of $1.30 and a 12 month high of $10.29. The firm's 50 day moving average price is $3.36 and its 200 day moving average price is $5.53.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.09. On average, research analysts expect that Acrivon Therapeutics, Inc. will post -2.49 EPS for the current year.

Insiders Place Their Bets

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc sold 1,054,669 shares of Acrivon Therapeutics stock in a transaction on Friday, April 25th. The shares were sold at an average price of $1.95, for a total value of $2,056,604.55. Following the completion of the transaction, the insider now directly owns 4,306,189 shares of the company's stock, valued at $8,397,068.55. This trade represents a 19.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 8.50% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ACRV shares. KeyCorp assumed coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They set an "overweight" rating on the stock. HC Wainwright lowered their price objective on Acrivon Therapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Acrivon Therapeutics in a research report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Acrivon Therapeutics presently has an average rating of "Buy" and an average price target of $21.80.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.